BLEOMYCIN FOR INJECTION DIN 02265982
Status: Marketed
Holder: FRESENIUS KABI CANADA LTD
Molecule: BLEOMYCIN (BLEOMYCIN SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous; Intramuscular; Intravenous; Intrapleural |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01DC01 BLEOMYCIN |
| Original market date | 20-Mar-2009 |
| Current status date | 25-Aug-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BLEOMYCIN (BLEOMYCIN SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02566346 | BLEOMYCIN FOR INJECTION | MARCAN PHARMACEUTICALS INC | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Approved |
| 02131692 | BLEOMYCIN FOR INJECTION USP | PFIZER CANADA ULC | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Marketed |
| 02367351 | BLEOMYCIN FOR INJECTION USP | SANDOZ CANADA INCORPORATED | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 17819 | 2016-02-26 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER AND PRODUCT NAME CHANGE |
| 9341 | 2008-01-30 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER NAME CHANGE |
| 8395 | 2006-11-08 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER NAME CHANGE |
| 6377 | 2005-03-30 | Abbreviated New Drug Submission (ANDS) |